Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prevnar 13 Post-Market Trials Must Confirm Surrogate Endpoint, Deal With Immunogenicity

Executive Summary

New post-marketing commitment will look at conjugate pneumonia vaccine when given in patients 50 and older who have already received Merck’s polysaccharide vaccine.


Related Content

Prevnar 13 Recommendation For Medicare Population May Be Short Lived
Regulatory News, In Brief
Analysis Says Prevnar 13 In Adults Cost-Effective, But Asks Same Questions As ACIP
Accelerated Approval Does Not Accelerate ACIP Recommendation For Prevnar 13 In Adults
Avastin’s Legacy May Be Quicker Withdrawal Process For New Approval Pathways
FDA Indicates Optimism Prevnar 13 Will Show Clinical Benefit In Confirmatory Trial
Pfizer Touts Prevnar 13 Superiority As Initial Vaccine In Older Persons Before ACIP


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts